Anton A Gryaznov, Ayman Saeyeldin, Mohamad Abdelbaky, Mohammad A Zafar, Maryam Tanweer, Dimitra Papanikolaou, Mahnoor Imran, Yupeng Li, Bulat A Ziganshin, John A Elefteriades
Controversy persists regarding the advisability of anticoagulation for the early period after biological surgical aortic valve replacement (AVR). We aim to examine the impact of various antithrombotic regimens on outcomes in a large cohort of biological AVR patients. Records of 1,111 consecutive adult patients who underwent surgical biological AVR at our institution between 2013 and 2017 were reviewed. Outcomes included stroke, bleeding, and death at 3 and 12 months. Treatment regimens included (1) no therapy, (2) anticoagulants (warfarin or Factor Xa inhibitors), (2) antiplateles (various), and (4) anticoagulants + antiplatelets...
May 18, 2020: American Journal of Cardiology